These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29089778)

  • 1. Treatment of pediatric
    D'Ostroph AR; So TY
    Infect Drug Resist; 2017; 10():365-375. PubMed ID: 29089778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland.
    van Engen A; Casamayor M; Loftus F; Coen M; Garnham A; Watt M; Lacey L
    J Health Econ Outcomes Res; 2015; 2(2):192-206. PubMed ID: 37663580
    [No Abstract]   [Full Text] [Related]  

  • 5. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of
    Al-Jashaami LS; DuPont HL
    Gastroenterol Hepatol (N Y); 2016 Oct; 12(10):609-616. PubMed ID: 27917075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
    Whitney L; Nesnas J; Planche T
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
    Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
    J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.
    Wagner M; Lavoie L; Goetghebeur M
    Can J Infect Dis Med Microbiol; 2014 Mar; 25(2):87-94. PubMed ID: 24855476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
    Mizusawa M; Doron S; Gorbach S
    Drugs Aging; 2015 Aug; 32(8):639-47. PubMed ID: 26233437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.